カレントテラピー　33-5　サンプル page 21/32

このページは カレントテラピー　33-5　サンプル の電子ブックに掲載されている21ページの概要です。
秒後に電子ブックの対象ページへ移動します。
「電子ブックを開く」をクリックすると今すぐ対象ページへ移動します。

概要：
カレントテラピー　33-5　サンプル

Current Therapy 2015 Vol.33 No.5 65治療の進歩489参考文献1）Castelli WP, Garrison RJ, Wilson PW, et al：Incidence of coronaryheart disease and lipoprotein cholesterol levels. TheFramingham Study. JAMA 256：2835-2838, 19862）The multiple risk factor intervention trial（MRFIT）. Anational study of primary prevention of coronary heart disease.JAMA 235：825-827, 19763）The Lipid Research Clinics Coronary Primary PreventionTrial results. I. Reduction in incidence of coronary heart disease.JAMA 251：351-364, 19844）Report of the National Cholesterol Education ProgramExpert Panel on Detection, Evaluation, and Treatment ofHigh Blood Cholesterol in Adults. The Expert Panel. ArchIntern Med 148：36-69, 19885）Scandinavian Simvastatin Survival Study Group：Randomisedtrial of cholesterol lowering in 4444 patients withcoronary heart disease：the Scandinavian Simvastatin SurvivalStudy（4S）. Lancet 344：1383-1389, 19946）National Cholesterol Education Program. Second Report ofthe Expert Panel on Detection, and High Blood Cholesterol inAdults（Adult Treatment PanelⅡ）. Circulation 89：1333-1445, 1994, 19977）Expert Panel on Detection, Evaluation, and Treatment ofHigh Blood Cholesterol in Adults：Executive Summary ofThe Third Report of The National Cholesterol EducationProgram（NCEP）Expert Panel on Detection, Evaluation,And Treatment of High Blood Cholesterol In Adults（AdultTreatment PanelⅢ）. JAMA 285：2486-2497, 20018）Grundy SM, Cleeman JI, Merz CN, et al；National Heart,Lung, and Blood Institute；American College of CardiologyFoundation；American Heart Association：Implications ofrecent clinical trials for the National Cholesterol EducationProgram Adult Treatment PanelⅢguidelines. Circulation110：227-239, 20049）Stone NJ, Robinson J, Lichtenstein AH, et al；American Collegeof Cardiology/American Heart Association Task Forceon Practice Guidelines：2013 ACC/AHA guideline on thetreatment of blood cholesterol to reduce atherosclerotic cardiovascularrisk in adults：a report of the American Collegeof Cardiology/American Heart Association Task Force onPractice Guidelines. J Am Coll Cardiol 63：2889-2934, 201410）日本動脈硬化学会高脂血症診療ガイドライン検討委員会：高脂血症診療ガイドライン．動脈硬化 25：1-34, 199711）Matsuzaki M, Kita T, Mabuchi H, et al；J-LIT Study Group.Japan Lipid Intervention Trial：Large scale cohort study ofthe relationship between serum cholesterol concentrationand coronary events with low-dose simvastatin therapy inJapanese patients with hypercholesterolemia. Circ J 66：1087-1095，200212）日本動脈硬化学会編：動脈硬化性疾患診療ガイドライン2002年版．日本動脈硬化学会，東京，200213）Nakamura H, Arakawa K, Itakura H, et al；MEGA StudyGroup：Primary prevention of cardiovascular disease withpravastatin in Japan（MEGA Study）：a prospective randomisedcontrolled trial. Lancet 368：1155-1163, 200614）Yokoyama M, Origasa H, Matsuzaki M, et al；Japan EPAlipid intervention study（JELIS）Investigators：Effects ofeicosapentaenoic acid on major coronary events in hypercholesterolemicpatients（JELIS）：a randomiset open -label,blinded endpoint analysis. Lancet 369：1090-1098, 200615）日本動脈硬化学会：動脈硬化性疾患予防ガイドライン2007年版．協和企画，200716）NIPPON DATA80 Research Group：Risk assessment chartfor death from cardiovascular disease based on a 19-year follow-up study of a Japanese representative population. Circ J70：1249-1255, 200617）日本動脈硬化学会：動脈硬化性疾患予防ガイドライン2012年版．日本動脈硬化学会，東京，2012